Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Robert A. Lenz, the Head of Research and Development at Neumora Therapeutics , Inc. (NASDAQ:NMRA), has sold a portion of his holdings in the company. According to a recent SEC filing, Lenz sold 5,614 shares of common stock on February 18, 2025. The shares were sold at a weighted average price of $1.6714, resulting in a total transaction value of approximately $9,383. The transaction occurs as NMRA trades near its 52-week low of $1.60, with the stock down 91% over the past year. Despite current market valuation of $281 million, analysts maintain price targets ranging from $4 to $30, suggesting potential upside according to InvestingPro data.
The sale was conducted under Lenz’s Rule 10b5-1 trading plan, which was adopted on June 12, 2024. This plan allows for the automatic sale of shares to cover withholding obligations on vesting restricted stock units. Following this transaction, Lenz retains ownership of 309,092 shares in Neumora Therapeutics. For comprehensive insider trading analysis and 13 additional key insights about NMRA, visit InvestingPro, where you’ll find detailed research reports covering 1,400+ US stocks.
In other recent news, Neumora Therapeutics has announced significant leadership changes, with co-founder Paul L. Berns stepping in as CEO and chairman of the Board. The company also appointed Joshua Pinto, Ph.D., as president, Bill Aurora, Pharm.D., as chief operating and development officer, and Michael Milligan as chief financial officer. Meanwhile, Neumora is facing challenges following disappointing results from its KOSTAL-1 trial for the drug navacaprant, which failed to show consistent benefits for patients with major depressive disorder. As a result, RBC Capital downgraded Neumora’s stock from Outperform to Sector Perform, reducing the price target to $4.00 from $29.00.
Despite the setback, BofA Securities maintained a Buy rating, though it significantly lowered the price target to $7.00 from $22.00, citing potential positive outcomes from the ongoing KOSTAL-2 and KOSTAL-3 trials. H.C. Wainwright also reiterated a Buy rating with a $30.00 price target, expressing confidence in the drug’s mechanism and highlighting promising results among female patients. Mizuho (NYSE:MFG) Securities maintained an Outperform rating with a $20.00 price target, anticipating updates on the navacaprant program and emphasizing the company’s cash runway to mid-2026. Neumora plans to discuss its financial results and provide a business update during a conference call on March 3, 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.